Literature DB >> 2406513

DNA strand breaks in human leukocytes induced by chemotherapy and total body irradiation.

C Franssen1, P Boekema, T De Witte, J Wessels, A Van der Kogel, C Haanen.   

Abstract

The occurrence of DNA strand breaks and/or DNA alkali-labile sites in peripheral blood leucocytes was demonstrated ex vivo in three patients during and after bone marrow ablative chemotherapy and total body irradiation (TBI) with use of fluorometric analysis of the DNA unwinding rate in alkaline solution (FADU assay). DNA damage was apparent after cyclophosphamide administration and after TBI, related to the amount of the applied dose. In vivo repair occurred within 24 hours, although not to pretreatment values. Demethoxydaunorubicin and busulfan at the dosages used did not induce measurable DNA strand breaks. The experiences described may be developed further to study ex vivo the occurrence of DNA lesions in patients during and after anticancer treatment. Such studies may be of value in comparing the DNA damaging potential of different chemotherapeutic or radiotherapeutic regimens and as a biological assessment of DNA damage after nuclear casualties in cases where the dose is greater than 1-2 Gy and measurement can be made within due time after the ionizing exposure.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2406513     DOI: 10.1016/0145-2126(90)90151-x

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  Formation of cyclophosphamide specific DNA adducts in hematological diseases.

Authors:  L'Aurelle A Johnson; Bhaskar Malayappan; Natalia Tretyakova; Colin Campbell; Margaret L MacMillan; John E Wagner; Pamala A Jacobson
Journal:  Pediatr Blood Cancer       Date:  2011-07-25       Impact factor: 3.167

2.  Cytotoxicity, DNA cross-linking, and DNA single-strand breaks induced by cyclophosphamide in a rat leukemia in vivo.

Authors:  J Y Wang; G Prorok; W P Vaughan
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.